Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine
about
Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlationsIdentification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafilExtrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine.Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors.Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir.Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system.Clinically significant pharmacokinetic drug interactions with benzodiazepines.Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affectHuman drug metabolism and the cytochromes P450: application and relevance of in vitro models.Toxicological interactions between alcohol and benzodiazepines.Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes.Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro.Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity.Quantitative drug interactions prediction system (Q-DIPS): a dynamic computer-based method to assist in the choice of clinically relevant in vivo studies.Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies.Terfenadine-antidepressant interactions: an in vitro inhibition study using human liver microsomes.Effect of alosetron on the pharmacokinetics of alprazolam.In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans.Human cytochromes mediating gepirone biotransformation at low substrate concentrations.Effects of concomitant fluvoxamine on the metabolism of alprazolam in Japanese psychiatric patients: interaction with CYP2C19 mutated alleles.Interdose elevation in plasma cortisol during chronic treatment with alprazolam but not lorazepam in the elderly.Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine.Mechanism of cytochrome P450-3A inhibition by ketoconazole.Consumption of charcoal-broiled meat as an experimental tool for discerning CYP1A2-mediated drug metabolism in vivo.In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction.Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents.Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo.FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling.A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism.
P2860
Q24564971-248F0E39-A885-4FD8-A9EB-EF87AD874F6CQ28343408-23521F1F-F926-48F4-8ECA-EC8460F41494Q28362294-BB6BFEF0-9E84-483D-ABF6-45D8DDBE8AA8Q30577448-1A08BDEE-4580-4C74-AC8C-99ABE17AA370Q32064655-5B8884BF-55F6-4A59-91CC-C326BC65409AQ33186873-649DB76C-8B66-4719-AE68-F3A6CEFD3EAEQ33630990-C42FA8DC-AE43-434E-8253-C434D9A217F2Q33785867-D0448457-5465-457E-BECA-9764BA3C3F4CQ33838839-ADB43D8C-8ED0-4BBF-8764-301962D76FADQ34430456-5371CCA1-B291-4E34-BBD4-E908208E9BFDQ34624505-6E8B9C96-8A33-4054-9FC6-FF192E89DB14Q36053702-D4E10EA9-5597-41E8-9E2A-2BA9356B6909Q37780212-7F72AFED-9B76-427E-A681-1A94C061C3DCQ37845170-1BE6D8F1-922A-4E2B-B26A-0C2558986CA1Q40681049-F9D0D9C1-EB4D-4E68-81CE-D297C29D0A9DQ41186979-B9CB59FF-1810-4463-80DB-32C8FD92E2DFQ41848772-19594226-A569-41E5-A7D7-07604A30D3A3Q43576843-5CE0110D-0D02-4D76-9691-5462EE4B829AQ43824936-3E920198-4588-484A-8FF9-1218D0308315Q44347379-8C509459-8CCE-4130-8ACD-BB6FE96C9BB6Q44405619-07A7DABF-CF37-414E-A657-DAC0F2C089B0Q44705386-D8C50830-78DA-440D-A718-D9A5D10DDEAFQ45045266-A594813E-B275-4A1E-8D2D-CD271381F168Q45344293-435DB47D-C2DF-4A04-A3FF-F9FB0B2BFDBCQ46675103-5A8B0F24-8F0E-4361-BE42-A6847ECCAABCQ49166540-B1367A53-6EC5-4113-96DC-C6641D4C5266Q51562990-5031B62B-BE6F-40CF-B2FC-A1C5595D4562Q52041523-3D8C3727-6495-4002-8D04-07C24C369F60Q52205708-9004B764-7051-4E32-8FA2-F3068045BC8FQ52306429-27EA9E26-CBE8-4377-8FFA-A2DADC4AF82D
P2860
Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine
description
1994 nî lūn-bûn
@nan
1994 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Inhibitors of alprazolam metab ...... ts, ketoconazole and quinidine
@ast
Inhibitors of alprazolam metab ...... ts, ketoconazole and quinidine
@en
Inhibitors of alprazolam metab ...... ts, ketoconazole and quinidine
@nl
type
label
Inhibitors of alprazolam metab ...... ts, ketoconazole and quinidine
@ast
Inhibitors of alprazolam metab ...... ts, ketoconazole and quinidine
@en
Inhibitors of alprazolam metab ...... ts, ketoconazole and quinidine
@nl
prefLabel
Inhibitors of alprazolam metab ...... ts, ketoconazole and quinidine
@ast
Inhibitors of alprazolam metab ...... ts, ketoconazole and quinidine
@en
Inhibitors of alprazolam metab ...... ts, ketoconazole and quinidine
@nl
P2093
P2860
P1476
Inhibitors of alprazolam metab ...... ts, ketoconazole and quinidine
@en
P2093
D J Greenblatt
J S Harmatz
L L von Moltke
M M Cotreau-Bibbo
R I Shader
P2860
P356
10.1111/J.1365-2125.1994.TB04317.X
P407
P577
1994-07-01T00:00:00Z